| abstract |
Pyridyl-phthalazinedione (I)nwherenR1 and R2 are selected from the group consisting of hydrogen, halogen and methoxy, or wherein R1 and R2 together formnmethylene dioxide and their pharmaceutically acceptable salts, and pharmaceutical compositions containing itnan effective amount of glycine5 antagonist for use in the treatment of neurological disorders associated withnincreased excitability and glutamaterial neurotransmission dysfunction in animals and humans. |